GALNT10 Affects O‐Glycosylation of IGFBP7 to Promote Tumor Vascular Remodeling and Metastasis of Ovarian Cancer
Advanced Science · 2026
DOI: 10.1002/advs.202516106 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2026. Verfasst von Yanan Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Peking University Third Hospital, Beijing, China. Hauptthemen laut MEDLINE: Ovarian Neoplasms, N-Acetylgalactosaminyltransferases, Vascular Remodeling. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, China Postdoctoral Science Foundation, State Key Laboratory of Vascular Homeostasis and Remodeling Open Funding.
Abstract (Originalsprache)
Tumor metastasis represents a major determinant of prognosis in ovarian cancer. Accumulating evidence has demonstrated that the glycosylation of secretome proteins regulates cell communication in the tumor microenvironment, thereby affecting tumor metastasis; however, the underlying regulatory mechanisms remain unclear. In this study, we observed markedly elevated glycosylation levels in metastatic ovarian cancer and identified GALNT10 as a key glycosyltransferase that promotes EMT of ovarian cancer cells. Furthermore, GALNT10 enhances the extracellular secretion of IGFBP7 through O‐GalNAc glycosylation modification at the T188 site. IGFBP7 subsequently interacts with the CD93 receptor on endothelial cells, leading to vascular remodeling characterized by abnormal vascular formation and impaired vascular maturity. Moreover, we identified the GALNT10 inhibitor Luteolin, which effectively suppresses ovarian cancer metastasis, modulates the immunosuppressive tumor microenvironment through tumor vascular‐immune crosstalk, and exhibits synergistic effects with anti‐PD1 therapy. Collectively, our findings indicate that GALNT10 facilitates ovarian cancer metastasis through the induction of tumor cell EMT and tumor vascular dysfunction, suggesting that GALNT10 inhibitors represent a promising avenue for the development of novel therapeutic strategies in ovarian cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Peking University Third Hospital, Beijing, China.
- National Clinical Research Center for Obstetrics and Gynecology, Beijing, China.
- State Key Laboratory of Vascular Homeostasis and Remodeling, Peking University Third Hospital, Beijing, China.
- State Key Lab of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
ORCID-Profile: Yanan Zhang, Chunliang Shang
Förderung
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
- State Key Laboratory of Vascular Homeostasis and Remodeling Open Funding
- Peking University Clinical Scientist Training Program
- Fundamental Research Funds for the Central Universities
- Key Clinical Project of Peking University Third Hospital
- National Key Research and Development Program of China
- Clinical Medicine Plus X-Young Scholars Project
Zitieren
APA
Zhang, Y., Zuha, A., Wu, Z., Luo, A., Jin, B., Sun, Q., Li, Y., Liu, Q., Guo, H., & Shang, C. (2026). GALNT10 Affects O‐Glycosylation of IGFBP7 to Promote Tumor Vascular Remodeling and Metastasis of Ovarian Cancer. Advanced Science. https://doi.org/10.1002/advs.202516106
Vancouver
Zhang Y, Zuha A, Wu Z, Luo A, Jin B, Sun Q, et al. GALNT10 Affects O‐Glycosylation of IGFBP7 to Promote Tumor Vascular Remodeling and Metastasis of Ovarian Cancer. Advanced Science. 2026. doi:10.1002/advs.202516106
BibTeX
@article{Zhang2026,
author = {Zhang, Yanan and Zuha, Ayala and Wu, Zhangxin and Luo, Aiping and Jin, Bixia and Sun, Qinkun and Li, Yuan and Liu, Qiyu and Guo, Hongyan and Shang, Chunliang},
title = {GALNT10 Affects O‐Glycosylation of IGFBP7 to Promote Tumor Vascular Remodeling and Metastasis of Ovarian Cancer},
journal = {Advanced Science},
year = {2026},
doi = {10.1002/advs.202516106}
}
EUVIMED